Markham, Canada
Markham, Canada

Time filter

Source Type

Mayer M.,University of Waterloo | McCracken M.,University of Waterloo | Persic J.,Microbonds
Journal of Electronic Packaging, Transactions of the ASME | Year: 2013

The method is based on a microheater integrated next to a wire bonding pad (test pad) on a test chip. It is fabricated in CMOS technology without additional micromachining. The microheater consists of two polysilicon resistor elements, placed at opposite sides of the pad, operated in parallel using a constant voltage, each element extending over 30×70 lm with a resistance of ̃140 ω at room temperature, and is operated based on Joule heating. The polysilicon is located at least 20 lm but not more than 50 lm from the pad aluminum. To characterize the microheater, Al serpentine resistors are placed on and between the heaters next to the pad, serving as resistive temperature detectors, having resistances of about 9.4 ω at room temperature. With a constant operation voltage of 15 V, ̃140 mA of current and ̃2.1W of heating power are generated, resulting in a heat flux of ̃500 MW/m2. The thermal resistance of the heater is 200 K/W (i.e., loss coefficient of 5 mW/K). The maximum temperature measured on one of the microheater resistors was above 396 °C and was reached using 18 V within less than 5 s of voltage application starting at room temperature. When heating from 101 °C to 138 °C, even faster heating is possible, allowing the performance of highly accelerated thermocycles. These cycles are applied to a ball bond on the test pad. Compared to the 20 min cycles used by a standard test, the new microheater device performed cycles lasting 10 ms (5 ms on, 5ms off) which is 5 orders of magnitude faster. The released energy is typically 10 mJ per cycle. A 50 lm diameter ball was made using 25 lm diameter Au wire and bonded to the test pad. The effect of the microheater-cycling on the contact resistance values of ball bonds is described. Starting with typical contact resistance values around 2.5mω, the increase observed is between 4% and 7% after 5̃106 10 ms cycles (̃14 h). © 2013 by ASME.


Shah A.,University of Waterloo | Rezvani A.,University of Waterloo | Mayer M.,University of Waterloo | Zhou Y.,University of Waterloo | And 2 more authors.
Microelectronics Reliability | Year: 2011

Given the cost and performance advantages associated with Cu wire, it is being increasingly seen as a candidate to replace Au wire for making interconnections in first level microelectronics packaging. A Cu ball bonding process is optimized with reduced pad stress and splash, using a 25.4 μm diameter Cu wire. For ball bonds made with conventionally optimized bond force and ultrasonic settings, the shear strength is ≈140 MPa. The amount of splash extruding out of bonded ball interface is between 10 and 12 μm. It can be reduced to 3-7 μm if accepting a shear strength reduction to 50-70 MPa. For excessive ultrasonic settings, elliptical shaped Cu bonded balls are observed, with the minor axis of the ellipse in the ultrasonic direction and the major axis perpendicular to the ultrasonic direction. To quantify the direct effect of bond force and ultrasound settings on pad stress, test pads with piezoresistive microsensors integrated next to the pad and the real-time ultrasonic force signals are used. By using a lower value of bond force combined with a reduced ultrasound level, the pad stress can be reduced by 30% while achieving an average shear strength of at least 120 MPa. These process settings also aid in reducing the amount of splash by 4.3 μm. © 2010 Elsevier Ltd. All rights reserved.


Nguyen N.H.,University of Waterloo | Nguyen N.H.,Hanoi National University of Education | Hu A.,University of Waterloo | Persic J.,Microbonds | Wen J.Z.,University of Waterloo
Chemical Physics Letters | Year: 2011

This Letter presents the thermal stability and energetic reaction properties of palladium coated aluminum nanoparticles. The classical MD simulations are conducted using a new EAM force field. The results reveal that, when the initial temperature is higher than 600 K and lower than 900 K, a two-stage reaction may occur. At the first stage, the reaction rate is determined by the solid-state diffusion of Al atoms. At the second stage where the particle temperature is greater than the melting point of Al, the alloying reaction between the liquid Al core and the Pd shell happens with a much faster rate. © 2010 Elsevier B.V. All rights reserved.


Nan C.,University of Waterloo | Mayer M.,University of Waterloo | Zhou N.,University of Waterloo | Persic J.,Microbonds
Microelectronic Engineering | Year: 2011

With the rapid development of advanced microelectronic packaging technologies, research on fine-pitch wire bonding with improved reliability is driven by demands for smaller form factors and higher performance. In this study, thermosonic wire bonding process with a 20 μm wire for fine-pitch interconnection is described. To strengthen stitch bonds made in a gold-silver bonding system when the bonding temperature is as low as 150 °C, ball bumps (security bump) are placed on top of the stitch bonds. The ball-stitch bond and bump forming parameters are optimized using a design of experiment (DOE) method. A comparison of pull test results for stitch bonds with and without security bumps shows a substantial increase of the stitch pull force (PF) due to the use of security bonds. By varying the relative position of the security bumps to the stitch bonds via wedge shift offset (WSO), a WSO window ranging from 15 to 27 μm results in stitch PF higher than 7 gf, which is equivalent to an increase in average stitch PF of 118%. © 2011 Elsevier B.V. All rights reserved.


Pequegnat A.,University of Waterloo | Kim H.J.,University of Waterloo | Mayer M.,University of Waterloo | Zhou Y.,University of Waterloo | And 2 more authors.
Microelectronics Reliability | Year: 2011

The development of novel Cu wires for thermosonic wire bonding is time consuming and the effects of shielding gas on the electrical flame off (EFO) process is not fully understood. An online method is used in this study for characterizing Cu free air balls (FABs) formed with different shielding gas types and flow rates. The ball heights before (HFAB) and after deformation (Hdef) are responses of the online method and measured as functions of gas flow rate. Sudden changes in the slopes of these functions, a non-parallelity of the two functions, and a large standard deviation of the HFAB measurements all identify FAB defects. Using scanning electron microscope (SEM) images in parallel with the online measurements golf-club shaped and pointed shaped FABs are found and the conditions at which they occur are identified. In general FAB defects are thought to be caused by changes in surface tension of the molten metal during EFO due to inhomogeneous cooling or oxidation. It is found that the convective cooling effect of the shielding gas increases with flow rate up to 0.65 l/min where the bulk temperature of a thermocouple at the EFO site decreases by 19 °C. Flow rates above 0.7 l/min yield an undesirable EFO process due to an increase in oxidation which can be explained by a change in flow from laminar to turbulent. The addition of H 2 to the shielding gas reduces the oxidation of the FAB as well as providing additional thermal energy during EFO. Different Cu wire materials yield different results where some perform better than others. © 2010 Elsevier Ltd. All rights reserved.


Wang J.,University of Waterloo | Hu A.,University of Waterloo | Persic J.,Microbonds | Wen J.Z.,University of Waterloo | Norman Zhou Y.,University of Waterloo
Journal of Physics and Chemistry of Solids | Year: 2011

Thermal stability and reaction properties of AlCuO system, a mixture of 50200 nm aluminum nanoparticles passivated by nitrocellulose and 12 nm copper (II) oxide, were investigated with microstructure characterization, differential thermal analysis (DTA), and thermogravimetric analysis (TGA). Transmission electron microscopy observation confirmed that the passivation coating successfully hinders the oxidization. TGA revealed that the passivation shell does not influence the ignition temperature of the thermite reaction. Reaction chemistry of the nano-thermite was elucidated by heating the composite both in inert ambient and vacuum. It was found that the thermite reaction composes of three continuing steps: At 570 °C, Al is oxidized into Al2O 3 by reacting with CuO, which forms Cu2O and produces a significant amount of heat. Subsequently two endothermic reactions occur. Starting at 800 °C, alumina reacts with Cu2O and forms CuAlO 2. Above this temperature CuAlO2 will decompose and eventually produce alumina, Cu, and O2 at 1000 °C. Since the nano-thermite reaction pathway differs greatly from bulk thermite reactions, these results are important to develop a nano-thermite platform that can be used for a novel low cost, low temperature, and copper based microjoining and advance IC packaging. © 2011 Elsevier Ltd. All rights reserved.


TORONTO, ON / ACCESSWIRE / November 3, 2016 / THE JENEX CORPORATION (TSXV: JEN.H) ("Jenex" or the "Corporation"), Rob Fia, CEO and Chairman of Jenex, reports the Corporation has entered into an exclusive license agreement (the "License") with Luminar Media Group Inc. of Aventura, Florida to market Jenex's next generation thermal therapy insect device (the "Device"). Luminar has an extensive contact base with Over the Counter ("OTC") retail distribution channels in the US. Europe and Asia. The License is subject to TSX Venture Exchange approval. The License allows Luminar the exclusive right to market the Device in all markets outside of Canada including the United States, Europe and Asia. Jenex maintains the marketing rights for the Canadian market and will own all intellectual property related to the Device. Jenex is investigating various names to identify the Device and a trademark. The Device will incorporate a proprietary silver anti-microbial coating along with other new features. As previously announced, Jenex is working with Microbonds Inc., an advanced coatings and electrical design company, to complete the design of the Device. Jenex expects to have a working Device prototype in the next 30-45 days. Jenex is pleased to announce it has received an initial USD $25,000 as outlined in the License, which includes the following additional milestone payments: Jenex will receive a royalty payment equal to 10% of gross sales of the Device up to the first 100,000 units sold and 5% of gross sales of the Device thereafter. The royalty is payable quarterly. Luminar must meet minimum sales targets of 10,000 units sold in the first 12 months from signing the License, 50,000 units sold by 24 months following the signing of the License and 100,000 units sold by 36 months from signing of the License. Luminar must continue to sell a minimum of 100,000 units per year beyond 36 months from signing of the License. In exchange for the above milestone and royalty payments Jenex will commit to obtaining all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside of the U.S. deemed necessary to market the product. Jenex will use its current FDA license for its former thermal therapy insect device and intends to apply for a Class II medical device that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites including bees, wasps, hornets, mosquitoes, black flies, and jelly fish. Jenex received approval for the above claims from the FDA (United States) in 1997. Jenex will utilize its ISO 13485 Quality Management System in any market that Luminar intends to market. "We are pleased to be partnering with Luminar to market our new Device. We believe our next generation product will be revolutionary and rewarding for both companies. This License is an exciting development for our Company and shareholders and is due to 'Outside the Box' thinking at Luminar and all the hard work of our staff and valuable partners that have contributed to date. We will have more to report as we work towards finalizing a working prototype of the Device." "We are very excited about our new partnership with The Jenex Corporation. The license agreement is an excellent opportunity for Luminar to increase shareholder value by leveraging Jenex's unique thermal therapy device. Luminar will bring specialized expertise in marketing and digital media capabilities to the partnership with Jenex as we expand globally with this important new treatment device." Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Our company was started by entrepreneurs that have a vision to identify new tools to communicate with the audience. Our presence is a natural response to a new way of working in a changing landscape. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm. For more information contact us at Luminar Media Group Investor Relations, ir@gdee.rocks or visit us at www.gdee.rocks This press release contains forward-looking statements. More particularly, this press release contains statements which include the timing of the proposed Device prototype and the commitment of Jenex to obtain all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside the US. The forward-looking statements are based on certain expectations and assumptions made by Jenex. Although Jenex believes that those expectations and assumptions are reasonable, undue reliance should not be placed on the forward-looking statements because Jenex can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors and risks. In addition to other risks, there is a risk that the development of the Device prototype and the obtaining of regulatory approvals with the FDA and other regulatory requirements will be delayed. The forward-looking statements contained in this press release are made as of the date hereof. Jenex disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For Further information please contact: NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES TORONTO, ON / ACCESSWIRE / November 3, 2016 / THE JENEX CORPORATION (TSXV: JEN.H) ("Jenex" or the "Corporation"), Rob Fia, CEO and Chairman of Jenex, reports the Corporation has entered into an exclusive license agreement (the "License") with Luminar Media Group Inc. of Aventura, Florida to market Jenex's next generation thermal therapy insect device (the "Device"). Luminar has an extensive contact base with Over the Counter ("OTC") retail distribution channels in the US. Europe and Asia. The License is subject to TSX Venture Exchange approval. The License allows Luminar the exclusive right to market the Device in all markets outside of Canada including the United States, Europe and Asia. Jenex maintains the marketing rights for the Canadian market and will own all intellectual property related to the Device. Jenex is investigating various names to identify the Device and a trademark. The Device will incorporate a proprietary silver anti-microbial coating along with other new features. As previously announced, Jenex is working with Microbonds Inc., an advanced coatings and electrical design company, to complete the design of the Device. Jenex expects to have a working Device prototype in the next 30-45 days. Jenex is pleased to announce it has received an initial USD $25,000 as outlined in the License, which includes the following additional milestone payments: Jenex will receive a royalty payment equal to 10% of gross sales of the Device up to the first 100,000 units sold and 5% of gross sales of the Device thereafter. The royalty is payable quarterly. Luminar must meet minimum sales targets of 10,000 units sold in the first 12 months from signing the License, 50,000 units sold by 24 months following the signing of the License and 100,000 units sold by 36 months from signing of the License. Luminar must continue to sell a minimum of 100,000 units per year beyond 36 months from signing of the License. In exchange for the above milestone and royalty payments Jenex will commit to obtaining all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside of the U.S. deemed necessary to market the product. Jenex will use its current FDA license for its former thermal therapy insect device and intends to apply for a Class II medical device that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites including bees, wasps, hornets, mosquitoes, black flies, and jelly fish. Jenex received approval for the above claims from the FDA (United States) in 1997. Jenex will utilize its ISO 13485 Quality Management System in any market that Luminar intends to market. "We are pleased to be partnering with Luminar to market our new Device. We believe our next generation product will be revolutionary and rewarding for both companies. This License is an exciting development for our Company and shareholders and is due to 'Outside the Box' thinking at Luminar and all the hard work of our staff and valuable partners that have contributed to date. We will have more to report as we work towards finalizing a working prototype of the Device." "We are very excited about our new partnership with The Jenex Corporation. The license agreement is an excellent opportunity for Luminar to increase shareholder value by leveraging Jenex's unique thermal therapy device. Luminar will bring specialized expertise in marketing and digital media capabilities to the partnership with Jenex as we expand globally with this important new treatment device." Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Our company was started by entrepreneurs that have a vision to identify new tools to communicate with the audience. Our presence is a natural response to a new way of working in a changing landscape. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm. For more information contact us at Luminar Media Group Investor Relations, ir@gdee.rocks or visit us at www.gdee.rocks This press release contains forward-looking statements. More particularly, this press release contains statements which include the timing of the proposed Device prototype and the commitment of Jenex to obtain all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside the US. The forward-looking statements are based on certain expectations and assumptions made by Jenex. Although Jenex believes that those expectations and assumptions are reasonable, undue reliance should not be placed on the forward-looking statements because Jenex can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors and risks. In addition to other risks, there is a risk that the development of the Device prototype and the obtaining of regulatory approvals with the FDA and other regulatory requirements will be delayed. The forward-looking statements contained in this press release are made as of the date hereof. Jenex disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For Further information please contact: NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES


Miami, Florida , Nov. 04, 2016 (GLOBE NEWSWIRE) -- Luminar Media Group, Inc.  (Luminar, OTCMKTS: LRGR) and The Jenex Corporation (Jenex, NEX: JEN.H) are pleased to announce that the two companies have entered an exclusive license agreement for markets outside of Canada for Jenex’s novel thermal therapy device for use on insect bites and stings. The License allows Luminar the exclusive right to market the device in all markets outside of Canada including the United States, Europe and Asia. Jenex maintains the marketing rights for the Canadian market and will own all intellectual property related to the device.  Jenex is investigating various names to identify the device and intends to file trademark for the name that will also be licensed to Luminar.  The device will incorporate a proprietary silver anti-microbial coating along with other new features.  As previously announced, Jenex is working with Microbonds Inc., an advanced coatings and electrical design company, to complete the design of the device.  Jenex expects to have a working device prototype in the next 30-45 days. Jenex has received an initial USD $25,000 as outlined in the License, which also includes the following additional milestone payments: Jenex will receive a royalty payment equal to 10% of gross sales of the Device up to the first 100,000 units sold and 5% of gross sales of the Device thereafter. The royalty is payable quarterly.  Luminar must meet minimum sales targets of 10,000 units sold in the first 12 months from signing the License, 50,000 units sold by 24 months following the signing of the License and 100,000 units sold by 36 months from signing of the License. Luminar must continue to sell a minimum of 100,000 units per year beyond 36 months from signing of the License. In exchange for the above milestone and royalty payments Jenex will commit to obtaining all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside of the U.S. deemed necessary to market the product.  Jenex will use its current FDA license for its former thermal therapy insect device and intends to apply for a Class II medical device that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites including bees, wasps, hornets, mosquitoes, black flies, and jelly fish.  Jenex received approval for the above claims from the FDA (United States) in 1997. Jenex will utilize its ISO 13485 Quality Management System in any market that Luminar intends to market. “We are pleased to be partnering with Luminar to market our new device.  We believe our next generation product will be revolutionary and rewarding for both companies.  This License is an exciting development for our Company and shareholders and is due to ‘Outside the Box’ thinking at Luminar and all the hard work of our staff and valuable partners that have contributed to date.  We will have more to report as we work towards finalizing a working prototype of the device.” “We are very excited about our new partnership with The Jenex Corporation.  The license agreement is an excellent opportunity for Luminar to increase shareholder value by leveraging Jenex’s unique thermal therapy device.  Luminar will bring specialized expertise in marketing and digital media capabilities to the partnership with Jenex as we expand globally with this important new treatment device.” Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex’s philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries.  Our company was started by entrepreneurs that have a vision to identify new tools to communicate with the audience.  Our presence is a natural response to a new way of working in a changing landscape. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm. This news release contains forward-looking statements about our business, or financial condition and prospects, that reflect our assumptions and beliefs based on information currently available. The Company can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including risks discussed in the company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.


Patent
Microbonds | Date: 2012-11-20

A bonding wire comprises a core wire generally made of silver or a silver alloy, and the coating material is selected from one or more of: gold, palladium, platinum, rhodium. Alternatively, the core wire is generally made of copper or a copper alloy, and the coating material is selected from one or more of: palladium, platinum, rhodium, iridium, ruthenium. For both core wires, the coating material can be selected from a group of materials with the following characteristics: (1) the materials melting temperature is higher than the melting temperature of the core wire material, respectively; (2) the materials molten surface tension is higher than that of the core wire material, respectively; (3) the materials show a high resistance to oxide formation between the melting temperature of the core wire material and the melting temperature of the respective material itself; and (4) the coating material has the additional characteristic that the materials melting temperature is lower than the boiling temperature of the core wire material.


Loading Microbonds collaborators
Loading Microbonds collaborators